SomaLogic Licenses GNS Healthcare’s REFS™ technology for analysis of its SOMAscan®- derived proteomic data

Combining the world-leading proteomic and artificial intelligence/machine learning technologies to produce novel, actionable health insights across many diseases, conditions and markets July 17, 2018 – SomaLogic and GNS Healthcare announced today that SomaLogic has obtained a license to apply GNS Healthcare’s proprietary REFS™ (Reverse Engineering & Forward Simulation) causal machine learning technology to SomaLogic’s proprietary SOMAscan®-derived protein data […]

Rare Disease Report Covers Alexion-GNS REFS Licensing Agreement

Rare Disease Treatments to Be Discovered by Machine Learning and Simulation Platform August 10, 2017 – Earlier today, Alexion Pharmaceuticals was granted the licensing rights to operate GNS Healthcare’s Reverse Engineering and Forward Simulation (REFS) casual machine learning and simulation platform. Alexion intends to use the platform to accelerate both the research of rare diseases […]

GNS Healthcare Licenses REFS™ Causal Machine Learning and Simulation Platform to Alexion to Accelerate Discovery of New Treatments for Rare Diseases

CAMBRIDGE, Mass. – August 10, 2017– GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to large and diverse data sets to better match drugs and other health interventions to individual patients, today announced that it has entered into a license arrangement with Alexion for the rights to operate its REFS™ […]